Skip to content
Fencer Vulns
high 7.8

CVE-2026-12921 json

Use after free in AzeoTech DAQFactory

published 2026-06-25 4 mo ago modified 2026-10-25 14 d ago also EUVD-2026-39513

cvss
7.8
version 3.1, NVD
cisa kev
Not listed
not in CISA's catalog
epss
0.2%
EPSS 0.2% chance of exploitation in 30 days, percentile 8%
public exploits
0
none known

Summary

In AzeoTech DAQFactory versions 21.1 and prior, a Use After Free vulnerability can be exploited by an attacker using specially crafted .ctl files which can result in code execution.

Vendor advisories

What the vendors themselves say about their products: affected, fixed or not affected, and what to do.

cisa ICSA-26-169-02 updated cvss 7.8

AzeoTech DAQFactory (Update A)

  • AzeoTech DAQFactory <=21.1
    affected: mitigation “Users are discouraged from using documents from unknown/untrusted sources.”

From CISA ICS and IT advisories (CSAF, https://github.com/cisagov/CSAF), a U.S. Government work; changed: reduced to products, statuses and remediations. CISA notification · csaf

CISA SSVC

Exploitation
none
Automatable
no
Technical impact
total
Assessed
4 mo ago

Exploit prediction

0.19% chance of exploitation in the next 30 days, higher than 8% of all scored CVEs (FIRST EPSS, 2026-11-08).

CVSS scores

assigned by version score vector
CNA 4.0 8.4 CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N
CNA 4.0 8.4 CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
NVD 3.1 7.8 CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Affected products

  • AzeoTech DAQFactory

Classification

Weakness

References

Sources

Fencer Vulns keeps one entry per vulnerability: the CVE id wins, then GHSA, and records that alias each other are merged, except that two CVEs always keep separate entries. The same data is available as JSON.

CPEs and fixed versions use Anchore's correction of NVD's data: Added CPE configurations because not yet analyzed by NVD.